Car-t

AstraZeneca's CAR-T Therapy Shows Promise

AstraZeneca's in vivo CAR-T therapy has shown early responses in 50% of patients, according to Endpoints News.

In vivo CAR-T: A faster path—or just another promise?

In vivo CAR-T trials show promise, skipping lab processing.

Engineered Immune Cells Target Solid Tumors via Metabolites

In-Vivo CAR T Cell Breakthrough—But How Far From Patients?

Lab-grown CAR T cells bypass external editing—preclinical success against 3 cancers, a major leap for solid tumors.

In vivo CAR-T shows promise—but only in mice, for now

East Asian men with a missing Y chromosome in their pancreatic cells face 30% higher diabetes odds—*but only if their genetic risk is otherwise low*, per a *Nature Medicine* analysis of 200,000+ genomes.